New Peroxisome Proliferator-Activated Receptor Ago... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

New Peroxisome Proliferator-Activated Receptor Agonist (GQ-11) Improves Wound Healing in Diabetic Mice

Full text
Author(s):
Silva, Jacqueline C. [1] ; Pitta, Marina G. R. [2] ; Pitta, Ivan R. [2] ; Koh, Timothy J. [3] ; Abdalla, Dulcineia S. P. [1]
Total Authors: 5
Affiliation:
[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Clin & Toxicol Anal, Ave Prof Lineu Prestes 580, BR-05508000 Sao Paulo, SP - Brazil
[2] Univ Fed Pernambuco, Ctr Biol Sci, Core Therapeut Innovat, Recife, PE - Brazil
[3] Univ Illinois, Coll Appl Hlth Sci, Dept Kinesiol & Nutr, 1919 West Taylor St, 529 AHSB, Chicago, IL 60612 - USA
Total Affiliations: 3
Document type: Journal article
Source: ADVANCES IN WOUND CARE; v. 8, n. 9, p. 417-428, SEP 1 2019.
Web of Science Citations: 0
Abstract

Objective: Chronic wounds associated with diabetes are an important public health problem demanding new treatments to improve wound healing and decrease amputations. Monocytes/macrophages play a key role in sustained inflammation associated with impaired healing and local administration of peroxisome proliferator-activated receptor (PPAR)gamma agonists may modulate macrophage, improving healing. In this study, we investigated the effects of GQ-11, a partial/dual PPAR alpha/gamma agonist, on macrophage function and wound healing in diabetes. Approach: Wounds were surgically induced at the dorsum of C57BL/6J and BKS.Cg-Dock7(m) +/+ Lepr(db)/J (db/db) mice and treated with hydrogel (vehicle), pioglitazone or GQ-11, for 7 or 10 days, respectively. After treatment, wounds were analyzed histologically and by quantitative PCR (qPCR). In addition, bone marrow-derived macrophages (BMDM) were cultured from C57BL/6J mice and treated with vehicle, pioglitazone, or GQ-11, after challenge with lipopolysaccharide or interleukin-4 to be analyzed by qPCR and flow cytometry. Results: GQ-11 treatment upregulated anti-inflammatory/pro-healing factors and downregulated pro-inflammatory factors both in wounds of db/db mice and in BMDM. Innovation: Wounds of db/db mice treated with GQ-11 exhibited faster wound closure and re-epithelization, increased collagen deposition, and less Mac-3 staining compared with vehicle, providing a new approach to treatment of diabetic wound healing to prevent complications. Conclusion: GQ-11 improves wound healing in db/db mice, regulating the expression of pro- and anti-inflammatory cytokines and wound growth factors, leading to increased re-epithelization and collagen deposition. (AU)

FAPESP's process: 12/51316-5 - Study of the activity of biodrugs, PPARs agonists and natural products with therapeutic potential in atherosclerosis
Grantee:Dulcineia Saes Parra Abdalla
Support Opportunities: Research Projects - Thematic Grants
FAPESP's process: 16/00233-3 - "Action of a novel thiazolidinedione (GQ-11) in tissue repair process on experimental models of insulin resistance and vascular surgery.
Grantee:Jacqueline Cavalcante Silva
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 16/16850-1 - Modulation of tissue repair by a new thiazolidine compound (GQ-11) on experimental models of insulin resistance and visceral ischemia
Grantee:Jacqueline Cavalcante Silva
Support Opportunities: Scholarships abroad - Research Internship - Doctorate